Ac-[D-Tyr⁴⁶,Hyp⁴⁷,Thr⁴⁹,azaGly⁵¹,Arg(Me)⁵³,Trp⁵⁴]metastin(46-54) | 1234319-68-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Ac-[D-Tyr⁴⁶,Hyp⁴⁷,Thr⁴⁹,azaGly⁵¹,Arg(Me)⁵³,Trp⁵⁴]metastin(46-54)
• 英文别名: Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2；L-Tryptophanamide, N-acetyl-D-tyrosyl-(4R)-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl-2-azaglycyl-L-leucyl-N5-(imino(methylamino)methyl)-L-ornithyl-；(2S)-2-[[(2S,4R)-1-[(2R)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-N-[(2S,3R)-1-[[(2S)-1-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-[(N'-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]butanediamide
• CAS: 1234319-68-6
• 化学式: C₅₈H₈₀N₁₆O₁₄
• 分子量: 1225.37
• InChiKey: MWXWMWSUUYXMRA-GRKBUMBKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  88
• 可旋转键数：
  31
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  478
• 氢给体数：
  17
• 氢受体数：
  15

反应信息

• 作为产物：
  描述：

  、 Fmoc-L-苯丙氨酸 、 乙酸酐 、 Fmoc-O-叔丁基-L-苏氨酸 、 Fmoc-N-三苯甲基-L-天冬酰胺 、 Fmoc-O-叔丁基-D-酪氨酸 、 FMOC-L-硫代脯氨酸 生成 Ac-[D-Tyr⁴⁶,Hyp⁴⁷,Thr⁴⁹,azaGly⁵¹,Arg(Me)⁵³,Trp⁵⁴]metastin(46-54)
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• METASTIN DERIVATIVES AND USE THEREOF
  申请人：Asami Taiji

  公开号：US20090093615A1

  公开（公告）日：2009-04-09

  The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotrophic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids in the metastin derivative of the present invention, blood stability, solubility, etc. are more improved, gelation tendency is reduced, pharmacokinetics are also improved, and an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity is exhibited. Furthermore, the metastin derivative of the present invention has the effects of suppressing gonadotropic hormone secretion, suppressing sex hormone secretion, etc.

  本发明提供了稳定的metastin衍生物，具有优良的生物活性（抑制癌症转移的活性、抑制癌症生长的活性、促性腺激素分泌的活性、促性激素分泌的活性等）。通过将metastin的组成氨基酸替换为本发明的特定氨基酸，可以进一步改善血液稳定性、溶解度等，减少凝胶化倾向，改善药物代谢动力学，并表现出优异的抑制癌症转移或抑制癌症生长的活性。此外，本发明的metastin衍生物具有抑制促性腺激素分泌、抑制性激素分泌等效果。
• PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND
  申请人：XDCExplorer (Shanghai) Co., Ltd.

  公开号：EP3650464A1

  公开（公告）日：2020-05-13

  Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound represented by formula (1), and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.         Cap-AA1-AA2-XX3-Asn-AA5-AA6-AA7-Leu-AA9-AA10-P     (1)

  本发明公开了一种多肽化合物及其应用，以及一种含有该多肽化合物的组合物。本发明提供了一种由式（1）表示的多肽化合物及其药学上可接受的盐、同系物、溶液、晶型或原药。该化合物对 Kiss1R 具有良好的稳定性和活性。 Cap-AA1-AA2-XX3-Asn-AA5-AA6-AA7-Leu-AA9-AA10-P (1)
• Methods of treating female infertility
  申请人：Myovant Sciences GmbH

  公开号：US11013780B2

  公开（公告）日：2021-05-25

  Further according to the present disclosure, there are methods for promoting egg maturation in assisted reproductive technologies, such as in in vitro fertilization (IVF) or in an embryo transfer (ET) process. There are also methods for decreasing the rate of ovarian hyperstimulation syndrome (OHSS), providing comparable or improved pregnancy rates, decreasing the time to pregnancy, and inhibiting premature ovulation. The methods include the step of administering a therapeutically effective amount of an active pharmaceutical ingredient of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl) hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharmaceutically acceptable salt thereof.

  此外，根据本公开内容，还有在辅助生殖技术中促进卵子成熟的方法，例如在体外受精（IVF）或胚胎移植（ET）过程中。还有降低卵巢过度刺激综合征（OHSS）发生率、提供可比或改进的妊娠率、缩短妊娠时间和抑制过早排卵的方法。这些方法包括给药治疗有效量的活性药物成分2-(N-乙酰基-D-酪氨酰-反式-4-羟基-L-脯氨酰-L-天冬氨酰-L-苏氨酰-L-苯丙氨酰)肼基甲酰基-L-亮氨酰-Nω-甲基-L-精氨酰-L-色氨酰胺或其药学上可接受的盐。
• [EN] PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND<br/>[FR] COMPOSÉ PEPTIDIQUE ET SON APPLICATION, ET COMPOSITION CONTENANT UN COMPOSÉ PEPTIDIQUE<br/>[ZH] 一种肽类化合物、其应用及含其的组合物
  申请人：XDCEXPLORER SHANGHAI CO LTD

  公开号：WO2019007383A1

  公开（公告）日：2019-01-10

  本发明公开了一种肽类化合物、其应用及含其的组合物。本发明提供了一种如式(1)所示的肽类化合物、其药学上可接受的盐、其互变异构体、其溶剂合物、其晶型或其前药。该化合物稳定性较佳且对Kiss1R的活性较佳。
• DEUTERATED IMIDAZOLIDINEDIONE COMPOUNDS AND THEIR USES
  申请人：Hinova Pharmaceuticals Inc.

  公开号：US20190298696A1

  公开（公告）日：2019-10-03

  Provided herein is a compound of Formula I having androgen receptor antagonistic properties and methods of using the compound to more efficiently and efficaciously reduce the concentration of prostate specific antigen (PSA) and treat male hormone-related diseases such as prostate cancer, breast cancer, alopecia, hair loss, acne and adolescent acne. Also provided are methods of reducing the plasma concentration of prostate specific antigen (PSA) in a subject with elevated PSA comprising administering to the subject a therapeutically effective amount of the compound.